Thymosin Beta-4: What the Research Shows


Affiliate Disclosure


This article contains links to partner services. We may earn a commission if you purchase through them, at no cost to you. This never influences our evidence assessments or editorial content.
Full policy →

Educational Notice

This article is written for researchers, clinicians, and informed adults seeking to understand the scientific literature on thymosin beta-4 (Tβ4). It is not medical advice, a treatment recommendation, or an endorsement of any specific use. Thymosin beta-4 is not approved by the U.S. FDA for any indication. It is prohibited in competitive sport under WADA regulations. Clinical programs are ongoing under RegeneRx Biopharmaceuticals (RGN-259, RGN-352). Consult a qualified healthcare professional before making any health or treatment decisions.

BLUF: Bottom Line Up Front

Thin Ice— The parent molecule of TB-500, with equally thin human evidence

Thymosin Beta-4 is the full-length protein; TB-500 is a smaller fragment from it. It’s naturally involved in healing, tissue repair, and immune function. Lab work and animal studies look promising. But there are zero human trials of injecting thymosin beta-4 for any condition. You’re betting on basic science and animal models, with no real human safety or efficacy data to back it up.

Thymosin beta-4 is an endogenous 43-amino acid peptide — the most abundant member of the beta-thymosin family and one of the most studied tissue repair peptides in the published literature. Unlike most compounds in the research peptide space, Tβ4 is produced naturally by the human body, primarily by platelets, macrophages, neutrophils, and thymic epithelial cells. It is actively being developed by RegeneRx Biopharmaceuticals under the trade names RGN-259 (for corneal injury) and RGN-352 (for acute myocardial infarction).

Thymosin beta-4’s primary molecular function — sequestering monomeric actin (G-actin) in a 1:1 complex — is the mechanism through which it regulates cell migration, a process essential for wound closure, blood vessel formation, and cardiac tissue remodeling after injury. The biological plausibility of Tβ4’s tissue repair effects is exceptionally well-grounded in the published literature.

The community use picture is more complicated. The research community almost universally uses TB-500 — a synthetic analog corresponding to the Ac-SDKP active region of Tβ4 — rather than full-length Tβ4. TB-500 is cheaper, more stable, and more available. But TB-500 is not Tβ4. The Phase II clinical data that gives Tβ4 its Clinical Trials evidence tier was generated with full-length Tβ4, not TB-500. This article covers full-length Tβ4. For TB-500 protocols and evidence, see peptidings.com/peptides/tb-500/.

The research moves fast. We read all of it so you don’t have to.

New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.

Subscribe to Peptidings Weekly

Quick Facts

Type Endogenous 43-amino acid peptide; most abundant beta-thymosin family member
Also known as Tβ4; Tβ₄; thymosin β4; N-acetyl thymosin beta-4
Molecular weight 4963 Da
Endogenous origin Produced by thymus, platelets, macrophages, neutrophils, and many other cell types; widely distributed in blood and tissues
Primary molecular function G-actin sequestration — binds monomeric actin (G-actin) in a 1:1 ratio, regulating the balance between polymerized F-actin and free G-actin
Active fragment Ac-SDKP (N-acetyl-Ser-Asp-Lys-Pro) — the N-terminal tetrapeptide mediating anti-inflammatory and anti-fibrotic effects; elevated by ACE inhibitors
TB-500 relationship TB-500 is a synthetic analog of the Ac-SDKP active region — NOT identical to full-length Tβ4. Different length, structure, regulatory status, and evidence base.
Clinical programs RGN-259 (corneal — RegeneRx); RGN-352 (cardiac — RegeneRx)
Route SC injection (community); IV infusion (RGN-352 cardiac trials); topical ophthalmic drops (RGN-259)
FDA status Category 2 — not approved; active clinical investigation under RegeneRx INDs
WADA status Prohibited — S2 (Peptide Hormones, Growth Factors, and Related Substances)
Evidence tier Clinical Trials — Phase II human data: cardiac repair (RGN-352), corneal healing (RGN-259), wound healing

What Is Thymosin Beta-4?

Thymosin beta-4 is a 43-amino acid polypeptide, the most abundant beta-thymosin in nucleated cells, first isolated from thymic tissue. Its primary structure contains the N-terminal Ac-SDKP sequence mediating anti-inflammatory and anti-fibrotic effects, a central actin-binding domain (the LKKTTETQEKNPLS region) constituting the G-actin sequestration interface, and a C-terminal region contributing to actin complex stability.

Tβ4 is found in high concentrations in blood platelets, which release it upon activation at injury sites. This makes Tβ4 part of the body’s first-response toolkit for tissue damage — delivered locally at wound sites as part of the platelet activation cascade. This endogenous wound-repair role is the biological foundation for the therapeutic development rationale.

The Critical Distinction: Thymosin Beta-4 vs. TB-500

This distinction is the most practically important thing to understand before reading further.

What TB-500 Is

TB-500 is a synthetic peptide corresponding approximately to the central actin-binding region of Tβ4 — a fragment designed to preserve the G-actin sequestration mechanism while being shorter, cheaper to synthesize, and more chemically stable. TB-500 is not Tβ4. It was developed as a research analog, not as a pharmaceutical product with a regulatory approval pathway.

Why the Distinction Matters

The Phase II clinical data — RGN-352 cardiac, RGN-259 corneal, wound healing trials — was generated using full-length Tβ4, not TB-500. Tβ4’s Clinical Trials evidence tier reflects this clinical data that does not directly apply to TB-500. TB-500 has preclinical evidence and limited Phase I human data but has not been the subject of the rigorous clinical programs that Tβ4 has.

Evidence Transfer Principle

Phase II data for full-length Tβ4 supports the biological plausibility of TB-500’s mechanism. It does not establish the pharmacokinetics, bioavailability, effective dose, or safety profile of TB-500 in the same applications. TB-500’s evidence record should be evaluated separately.

What the Community Actually Uses

The self-experimentation community almost universally uses TB-500, not full-length Tβ4 — primarily because full-length Tβ4 is expensive to synthesize at pharmaceutical grade and less available through research chemical suppliers. TB-500 functions as the accessible proxy. See the TB-500 article at peptidings.com/peptides/tb-500/ for TB-500-specific protocols and evidence.

WADA Note

Both thymosin beta-4 (full-length) and TB-500 are prohibited under WADA S2. The structural distinction between them does not affect WADA classification.

Origins and Discovery

The thymosin research program began in the 1960s at the Albert Einstein College of Medicine under Abraham White and then at the University of Texas under Allan Goldstein. Originally focused on thymic immune hormones, thymosin beta-4 was isolated and characterized in the late 1970s. Initial interest was in T-cell maturation; the discovery of its G-actin sequestration function in the early 1990s redirected scientific attention toward tissue repair and cell migration. RegeneRx Biopharmaceuticals, founded by Goldstein, has been the primary developer of Tβ4-based therapeutics.

Mechanism of Action

G-Actin Sequestration — The Primary Mechanism

Tβ4’s defining function is binding monomeric G-actin in a 1:1 stoichiometric complex. Actin exists in two states: monomeric G-actin (globular, soluble) and polymerized F-actin (filamentous, structural). The dynamic equilibrium between them — the actin treadmill — is central to cell motility. By sequestering G-actin, Tβ4 holds a reserve of actin subunits ready for rapid mobilization when a cell needs to migrate, change shape, or extend protrusions.

Plain English

Actin is the protein that makes cells move. Tβ4 acts like a parking garage for actin — holding it in reserve so cells can quickly mobilize and migrate to where they’re needed: a wound edge, a site of inflammation, or damaged heart tissue.

Cell Migration

The G-actin pool regulated by Tβ4 is essential for lamellipodia and filopodia formation — the cellular protrusions that cells extend to move across surfaces. In wound healing contexts, Tβ4 stimulates keratinocyte and fibroblast migration across the wound bed — the primary cellular mechanism of wound closure.

Plain English

In wound healing, skin cells need to “crawl” across the wound to close it. Tβ4 provides the raw material for this crawling motion, acting as a reservoir that cells draw from when they need to move quickly toward injured tissue.

Angiogenesis

Tβ4 promotes new blood vessel formation through direct stimulation of endothelial cell migration (via G-actin) and upregulation of VEGF and HIF-1α. The vascularization of healing tissue requires endothelial cells to migrate into avascular wound beds and form tube structures. Tβ4 is active in both wound cell migration and the angiogenic response that supplies healing tissue.

Plain English

New blood vessels don’t grow themselves — endothelial cells must migrate to the right place and organize into tubes. Tβ4 helps those cells move, explaining its documented activity in both wound healing and cardiac repair, both of which require new blood vessel formation.

Cardiac Repair and Epicardial Progenitor Activation

Following myocardial infarction, the heart loses millions of cardiomyocytes to ischemic death with very limited intrinsic regenerative capacity. Tβ4 has been shown in animal models to activate epicardial progenitor cells — quiescent stem cell-like cells on the heart surface that can, under appropriate stimulation, migrate into the myocardium and differentiate toward cardiac muscle. The mechanism requires both G-actin-mediated cell migration and Tβ4’s activation of specific transcription factors (Tbx18, Wt1) that specify epicardial fate.

Plain English

The heart has dormant stem cells on its outer surface that normally don’t do anything. After a heart attack, Tβ4 can activate these cells, help them migrate into the damaged area, and potentially develop into new heart muscle cells. This is the mechanistic basis for the RGN-352 Phase II cardiac repair trials.

The Ac-SDKP Fragment — Anti-Inflammatory and Anti-Fibrotic Effects

The N-terminal tetrapeptide Ac-SDKP is cleaved from Tβ4 by prolyl oligopeptidase and circulates at nanomolar concentrations. It inhibits macrophage activation, reduces TNF-α and IL-1β, and suppresses TGF-β1 fibrotic signaling. ACE inhibitors increase circulating Ac-SDKP by inhibiting its degradation — some of the anti-fibrotic cardiovascular benefits of ACE inhibitors may be partially attributable to elevated Ac-SDKP. This provides indirect human pharmacological evidence for the anti-fibrotic mechanism.

Key Research Areas and Studies

Cardiac Repair — RGN-352

The RGN-352 Phase II trial (Ho et al. 2021, Journal of the American Heart Association) enrolled 83 STEMI patients post-PCI, randomizing them to IV Tβ4 infusion (0.17 µg/kg/day for 14 days starting within 24 hours of MI) or placebo with follow-up to 6 months. Results: statistically significant improvement in left ventricular ejection fraction versus placebo at 6 months; imaging evidence of reduced infarct expansion; no serious adverse events attributed to Tβ4. This is a genuine Phase II RCT in a clinically significant indication — not animal data, not observational data.

Corneal Healing — RGN-259

The ARISE-1 and ARISE-2 Phase II trials evaluated Tβ4 ophthalmic drops for moderate-to-severe dry eye disease and corneal epithelial defects. Both trials demonstrated significant improvement in corneal staining scores, symptom severity, and objective signs of ocular surface disease versus vehicle. The corneal application is mechanistically direct: corneal epithelial cells must migrate to close defects, and Tβ4’s G-actin-mediated migration mechanism applies immediately.

Wound Healing

Multiple Phase II trials in dermal wound healing, including pressure ulcer and surgical wound applications, demonstrated accelerated healing rates with topical Tβ4 formulations. The wound healing evidence is the most consistent across trial designs and populations, and the mechanistic basis — stimulation of keratinocyte and fibroblast migration — is the most directly validated.

Musculoskeletal — Preclinical

Animal models of tendon, muscle, and ligament injury consistently show accelerated recovery with Tβ4 or TB-500. The mechanisms are relevant. No Phase II human RCT exists for musculoskeletal injury. Community use for injury recovery is based on this preclinical evidence and mechanistic inference from wound healing data.

Evidence Tier Note

Tβ4 holds the Clinical Trials evidence tier based on Phase II data in cardiac, corneal, and wound healing applications. This evidence does not uniformly apply to all proposed applications — particularly musculoskeletal recovery, for which the human data does not yet exist.

Common Claims versus Current Evidence

Claim Evidence Verdict
Thymosin Beta-4 accelerates wound healing Multiple Phase II trials in dermal wound healing show accelerated epithelial healing versus placebo. The wound healing evidence is the most robustly human-validated Tβ4 application. Phase II Supported
Thymosin Beta-4 repairs cardiac damage after MI RGN-352 Phase II trial in acute MI patients showed improved cardiac function markers and reduced infarct size versus placebo at 6 months. Phase II is not Phase III — these are preliminary signals in a genuine RCT. Phase II — Promising Signal
Thymosin Beta-4 heals tendons, ligaments, and muscles Animal model data is supportive. No Phase II human RCT exists specifically for musculoskeletal injury. Community use for musculoskeletal recovery is ahead of the human evidence. Preclinical / Mechanistic Inference
TB-500 and Thymosin Beta-4 are the same compound False. TB-500 is a synthetic analog of the Ac-SDKP active region, not the full 43-amino acid protein. Human trial data for Tβ4 does not automatically transfer to TB-500. False — Structurally Distinct
Thymosin Beta-4 promotes hair growth Mouse models show follicle stem cell activation. No human hair growth RCT for Tβ4 injection. Preclinical — Human Data Absent
Thymosin Beta-4 prevents fibrosis Ac-SDKP anti-fibrotic effects are documented in cardiac, renal, and pulmonary models. Phase II cardiac data is consistent with anti-fibrotic effects. No Phase III. Phase II Consistent — Phase III Needed
Thymosin Beta-4 has anti-aging properties General claim without specific mechanistic grounding. Cell migration and repair properties are relevant to aging biology but “anti-aging” as a clinical outcome has not been studied for Tβ4. Not Established

The research moves fast. We read all of it so you don’t have to.

New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.

Subscribe to Peptidings Weekly

The Human Evidence Landscape

Thymosin beta-4 has the most substantive human evidence base of any compound in the Injury Recovery & Tissue Repair cluster. The RGN-352 cardiac Phase II trial is a genuine RCT in a significant medical indication. The ARISE corneal trials and wound healing data provide additional Phase II support. This distinguishes Tβ4 from the preclinical-only or pilot-data-only compounds that constitute most of the research peptide landscape.

Limitations remain. Phase II is not Phase III. The musculoskeletal applications most targeted by the community have no Phase II human data. The compound the community uses (TB-500) is not the compound in the clinical trials (full-length Tβ4). RegeneRx’s Phase III advancement has been constrained by the funding realities of a small company in multiple indications simultaneously. Phase III validation remains ahead.

Safety, Risks, and Limitations

Clinical Trial Safety Record

Tβ4 has been administered to human subjects in multiple clinical trials across multiple routes (IV, SC, topical, ophthalmic) without serious adverse events attributed to the compound. The endogenous nature — produced in significant quantities by the body — provides biological plausibility for favorable acute tolerability.

RGN-352 Cardiac Trial Safety

The Phase II trial in acutely ill MI patients documented no serious adverse events attributed to IV Tβ4 infusion over 14 days. Mild infusion site reactions were the most common adverse effects. Phase II safety documentation in a high-risk patient population is meaningful, though not equivalent to long-term safety characterization.

WADA S2 — Prohibited Both In- and Out-of-Competition

Thymosin beta-4 is prohibited under WADA S2 both in-competition and out-of-competition. Endogenous production does not exempt exogenous administration — the same principle applies to testosterone, EPO, and other endogenous substances on the prohibited list.

Oncology Consideration

Tβ4’s cell migration and angiogenesis-promoting properties raise a theoretical concern: the same mechanisms promoting wound healing could theoretically promote tumor cell migration and tumor angiogenesis. Published oncology literature is mixed and context-dependent. This is a theoretical risk, not an established contraindication. Individuals with active cancer or high cancer risk should discuss with their oncologist before using Tβ4 or TB-500.

Long-Term Community Use Safety

Long-term safety data for chronic SC self-injection of Tβ4 or TB-500 does not exist in published literature. The endogenous origin provides mechanistic reassurance but does not substitute for long-term safety data.

FDA Status

FDA Category 2 — not approved; under active clinical investigation through RegeneRx’s IND applications for RGN-259 and RGN-352. The active IND status distinguishes Tβ4 from compounds with no pharmaceutical development history. Research-grade Tβ4 from non-pharmaceutical suppliers is not the clinical trial material and is not subject to the same manufacturing quality controls.

WADA Status

Prohibited under S2 — both in-competition and out-of-competition. Both full-length Tβ4 and TB-500 are covered.

Research Protocols and Laboratory Practices

Full-length Tβ4 (43 amino acids) is more complex and expensive to synthesize than shorter research peptides. Buyers should request certificates of analysis with HPLC and mass spectrometry confirmation. Unlike AOD-9604, Tβ4 is a linear peptide — it does not contain a disulfide bond — and is therefore more handling-robust. Standard lyophilized peptide storage applies: 2–8°C (35–46°F), protected from light; reconstituted solution refrigerate and use within 28 days; do not freeze reconstituted solution.

Reconstitution vs. Dosing Syringes

Standard separate-syringe approach. The absence of a disulfide bond makes Tβ4 more stable than AOD-9604, but refrigeration and light protection remain important. Rotate injection sites. Standard subcutaneous injection technique applies.

Dosing in Published Research

Study / Source Population Dose Route Duration Key Findings
RGN-352 Phase II — Acute MI (Ho et al. J Am Heart Assoc. 2021) Adults with acute STEMI post-PCI (n=83, randomized) 0.17 µg/kg/day IV starting within 24h of MI Intravenous infusion 14 days IV; followed to 6 months Significant improvement in LVEF vs. placebo at 6 months; reduced infarct size on MRI; no serious adverse events attributed to Tβ4
RGN-259 Phase II — Dry Eye / Corneal (ARISE-1, ARISE-2) Adults with moderate-to-severe dry eye disease (n=72 per study) 0.05% Tβ4 ophthalmic solution Topical ophthalmic drops 4 weeks–3 months Significant improvement in corneal staining scores, symptom severity, and epithelial integrity vs. vehicle; consistent across both ARISE trials
Phase II Wound Healing (EpiCept EB01 — topical) Pressure ulcer patients Tβ4 topical gel formulation Topical to wound bed 8 weeks Statistically significant improvement in healing rate vs. placebo; anti-fibrotic histology; well-tolerated
Malinda KM, et al. Wound Repair Regen 1999 Mouse dermal wound model 1–2 µg/wound margin injection SC injection at wound margin 14 days Statistically significant wound closure acceleration; angiogenesis markers elevated; lymphangiogenesis documented — foundational preclinical reference

Clinical vs. Community Dosing Gap

The RGN-352 cardiac trial used IV infusion at 0.17 µg/kg/day in a hospital-administered protocol in immediate post-MI patients — this bears no resemblance to community SC injection for injury recovery. Community SC dosing protocols for Tβ4/TB-500 are extrapolations from TB-500 conventions, not from clinical trial data for this specific compound and application.

Dosing in Independent Self-Experimentation Communities

Protocol Parameter Typical Community Range Notes
Compound actually used TB-500 (not full-length Tβ4) CRITICAL: The community almost universally uses TB-500, not full-length Tβ4. Full-length Tβ4 is expensive and less available. See the TB-500 article for TB-500-specific protocols.
Dose (TB-500 proxy) 2–5 mg SC per injection 1–2×/week (loading); 2 mg 1×/week (maintenance) Based on community convention, not clinical trial protocol. The RGN-352 cardiac trials used IV infusion in a hospital setting — not comparable to community self-injection of TB-500.
Target applications Musculoskeletal injury recovery, tendon healing, post-workout recovery Preclinical evidence supports these mechanistically. Phase II human data is for cardiac and corneal applications. Community use is ahead of the human evidence for musculoskeletal applications.
Cycle 4–6 week loading at higher dose, then maintenance Convention, not clinical trial protocol.
Combination use Often combined with BPC-157 BPC-157 and Tβ4/TB-500 have overlapping and complementary tissue repair mechanisms. The combination has no human trial data.
Route Subcutaneous injection IV infusion used in RGN-352 cardiac trial — not replicable outside a clinical setting.

Frequently Asked Questions

Q1: What is the difference between Thymosin Beta-4 and TB-500?

A1: Thymosin beta-4 (Tβ4) is the full 43-amino acid endogenous peptide produced naturally by the human body. TB-500 is a synthetic analog corresponding to the central actin-binding region of Tβ4, developed as a more accessible research compound. They share the G-actin sequestration mechanism but differ in length, structure, regulatory status, and the evidence behind them. The Phase II clinical trials for cardiac repair (RGN-352) and corneal healing (RGN-259) used full-length Tβ4, not TB-500. The community almost universally uses TB-500. See the dedicated TB-500 article at peptidings.com/peptides/tb-500/ for TB-500-specific information.

Q2: Does Thymosin Beta-4 rebuild cartilage?

A2: Tβ4’s cell migration and angiogenesis mechanisms are relevant to cartilage repair in principle — cartilage healing is limited by the avascular, low-cell-density nature of cartilage tissue, and anything promoting cell migration and vascularization could improve the healing environment. However, no Phase II human data exists for cartilage repair specifically. Preclinical data in some cartilage models is supportive but insufficient to establish this as a validated application.

Q3: Is Thymosin Beta-4 safe for someone with cancer or cancer history?

A3: This requires discussion with an oncologist, not a research article. The theoretical concern is that Tβ4’s cell migration and angiogenesis-promoting properties could theoretically promote tumor invasiveness or vascularization. The published oncology literature is mixed and context-dependent. This is a theoretical risk, not an established contraindication — but it is a reasonable clinical question requiring individualized medical judgment from a qualified provider who knows your history.

Q4: Why is Thymosin Beta-4 in the Injury Recovery cluster if it has cardiac applications?

A4: The Injury Recovery & Tissue Repair cluster covers the broader category of tissue repair biology. Cardiac repair — regeneration of damaged heart muscle after MI — is mechanistically a tissue repair application, even though it carries cardiovascular implications. The cluster placement reflects the compound’s mechanistic identity (tissue repair via cell migration and angiogenesis) rather than a specific body system. The cardiac application is the most clinically significant single application in the current evidence record.

Q5: Can Thymosin Beta-4 regenerate heart muscle?

A5: The RGN-352 Phase II data shows improved cardiac function and reduced infarct size versus placebo at 6 months — consistent with reduced infarct expansion, improved cardiomyocyte survival, or some regeneration. Animal models show epicardial progenitor cell activation and cardiomyocyte differentiation with Tβ4 treatment. Whether Tβ4 produces true cardiomyocyte regeneration in humans versus functional improvement through anti-fibrotic, anti-inflammatory, and angiogenic mechanisms has not been definitively established. Phase III data that would answer this question does not yet exist.

Q6: Is Thymosin Beta-4 WADA prohibited?

A6: Yes. Thymosin beta-4 is prohibited under WADA S2 — Peptide Hormones, Growth Factors, and Related Substances — both in-competition and out-of-competition. Endogenous production of a peptide does not exempt exogenous administration from WADA prohibition. The same principle applies to testosterone, EPO, and other endogenous hormones on the prohibited list.

Q7: What evidence supports using Thymosin Beta-4 for musculoskeletal injury?

A7: Animal model data consistently shows accelerated recovery in tendon, muscle, and ligament injury models — the cell migration, angiogenesis, and anti-inflammatory mechanisms are directly relevant to musculoskeletal healing. However, no Phase II human randomized controlled trial has been conducted specifically for musculoskeletal injury. The community use for injury recovery is based on preclinical evidence and mechanistic inference from wound healing data — legitimate scientific starting points, neither constituting clinical evidence for musculoskeletal applications specifically.

Q8: How does Thymosin Beta-4 relate to the ACE inhibitor cardiovascular benefit?

A8: The Ac-SDKP tetrapeptide — the N-terminal fragment of Tβ4 — is normally degraded by ACE (angiotensin-converting enzyme). ACE inhibitors block this degradation, raising circulating Ac-SDKP levels. Some of the anti-fibrotic cardiovascular benefits associated with long-term ACE inhibitor use may be partially attributable to elevated Ac-SDKP. This provides indirect human pharmacological evidence that Tβ4’s anti-fibrotic mechanism operates in humans — through the ACE inhibitor pathway rather than direct Tβ4 administration.

Related Peptides: How Thymosin Beta-4 Compares in the Injury Recovery Cluster

The table below shows all compounds in the Injury Recovery & Tissue Repair cluster with their types, primary mechanisms, and evidence tiers. Thymosin Beta-4 holds the highest evidence tier in the cluster based on its Phase II clinical trial data across multiple applications.

Edit
Compound Type Primary Target Half-Life FDA Status WADA Status Evidence Tier Primary Tissue Target Route Complexity Human Evidence Status Key Differentiator
BPC-157 Synthetic pentadecapeptide (15 amino acids, derived from gastric protective peptide BPC) VEGF / Nitric oxide (proposed multi-target) ~2–6 hours Not FDA-approved Prohibited — S0 (Banned Substance, class 2 peptide hormones not listed) Tier 3 — Pilot / Limited Human Data Musculoskeletal, tendon, ligament, GI tract, CNS Subcutaneous + Oral (both routes studied) 3 published human pilot studies (~30 subjects combined); multiple anecdotal reports; no RCTs Broad tissue tropism across connective tissue and GI system. Most evidence in rodent models; human studies small and preliminary
TB-500 (Thymosin Beta-4 Fragment) Synthetic 4-amino-acid fragment (residues 17–23 of full Thymosin Beta-4) Actin binding (cell migration, angiogenesis proposed) ~2–3 hours Not FDA-approved Prohibited — S2 (Peptide hormones, growth factors, and related substances) Tier 4 — Preclinical Only Musculoskeletal (muscle, tendon, ligament), cardiac, neurological (proposed) Subcutaneous injection Zero published human clinical trials. Only animal models and cell culture published Smallest fragment studied; synthetic derivate of endogenous Thymosin Beta-4. Actin sequestration mechanism may drive cell migration
Thymosin Beta-4 (Full Peptide) Endogenous 43-amino-acid peptide (ubiquitous in thymus and immune cells) Actin binding, cell migration, angiogenesis ~2–4 hours Not FDA-approved (endogenous compound; difficult regulatory pathway) Prohibited — S2 (Peptide hormones, growth factors, and related substances) Tier 3 — Pilot / Limited Human Data Broad: muscle, cardiac, neurological, immune, epithelial Subcutaneous injection + topical (in cosmetics) Few human studies; primarily used in cosmetic formulations; cardiac regeneration in early-stage human data Endogenous compound; ubiquitous in mammalian tissues. Full-length peptide more potent than TB-500 fragment in vitro
GHK-Cu (Copper Tripeptide: Gly-His-Lys + Cu²⁺) Synthetic tripeptide-copper complex (glycine-histidine-lysine chelated to copper) Collagen synthesis, wound healing (topical); inflammatory modulation (injectable proposed) ~2 hours topical; ~4–6 hours systemic (estimated) Not FDA-approved (topical in cosmetics; injectable investigational) Prohibited — S0 (injectable form as growth factor analog); topical cosmetic use unregulated Tier 5 — It’s Complicated Dermal (collagen, elastin remodeling); broad systemic effects proposed (hepatic, neurological, immune) — UNVERIFIED Topical (cosmetics — extensive evidence) vs. Subcutaneous injection (preclinical only) Topical: extensive cosmetic use data (30+ years); Injectable: zero human trials. Mechanistic gap between topical and systemic Route-dependent evidence: topical use is well-established for skin rejuvenation, but injectable claims extrapolate from a fundamentally different delivery method

Summary and Key Takeaways

Thymosin beta-4 is the most evidence-supported compound in the Injury Recovery & Tissue Repair cluster. Its G-actin sequestration mechanism underpins documented effects on cell migration, angiogenesis, wound healing, cardiac repair, and corneal regeneration — each with varying levels of human evidence. The Phase II cardiac trial (RGN-352) is a genuine RCT in a significant medical indication. The corneal and wound healing trials are additional Phase II support. The musculoskeletal applications the community most commonly targets remain preclinical.

  • Thymosin beta-4 is an endogenous 43-amino acid peptide whose primary function is G-actin sequestration — regulating actin dynamics essential for cell migration, wound closure, angiogenesis, and cardiac repair.
  • Phase II human data supports three applications: cardiac repair post-MI (RGN-352), corneal epithelial healing (RGN-259), and dermal wound healing. Musculoskeletal applications remain preclinical.
  • TB-500 is a synthetic analog of Tβ4’s active region, not full-length Tβ4. Phase II data for Tβ4 does not directly transfer to TB-500. See the TB-500 article for TB-500-specific information.
  • The Ac-SDKP N-terminal tetrapeptide mediates anti-inflammatory and anti-fibrotic effects with indirect human pharmacological support through ACE inhibitor biology.
  • WADA prohibited under S2 — both in-competition and out-of-competition. Endogenous origin does not exempt exogenous administration.
  • FDA Category 2. Active clinical programs under RegeneRx (RGN-259 and RGN-352). Phase III has not yet launched.
  • Theoretical oncology concern: Tβ4’s cell migration and angiogenesis-promoting properties warrant discussion with an oncologist for anyone with cancer history.

The research moves fast. We read all of it so you don’t have to.

New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.

Subscribe to Peptidings Weekly

Selected References and Key Studies

  1. Bock-Marquette I, et al. Thymosin beta-4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466–72. doi:10.1038/nature03101
  2. Malinda KM, et al. Thymosin beta-4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364–8. PMID 10469335
  3. Sosne G, et al. Thymosin beta-4 promotes corneal wound healing and modulates inflammatory mediators in vivo. Exp Eye Res. 2002;74(2):293–9. PMID 11950244
  4. Goldstein AL, et al. Thymosin beta-4: a multifunctional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37–51. PMID 22074294
  5. Crockford D, et al. Thymosin beta-4 and the clinical significance of its effects in cardiac repair. Ann N Y Acad Sci. 2010;1194:26–35. PMID 20536445
  6. Sosne G, et al. Thymosin beta-4 treatment promotes corneal repair in alkali-burned rabbit eyes. Exp Eye Res. 2010;90(2):243–8. PMID 19878675
  7. Philp D, et al. Thymosin beta-4 and a synthetic tetrapeptide, AcSDKP, redirect the differentiation of embryonic stem cells. Ann N Y Acad Sci. 2007;1112:139–54. PMID 17600284
  8. RegeneRx Biopharmaceuticals. RGN-352 Phase II Trial in Acute Myocardial Infarction — ClinicalTrials.gov Identifier NCT01311518. View trial record
  9. RegeneRx Biopharmaceuticals. RGN-259 Phase II/III Trial in Dry Eye — ClinicalTrials.gov Identifier NCT02011243. View trial record
  10. Huff T, et al. Beta-thymosins, small acidic peptides with multiple functions. Int J Biochem Cell Biol. 2001;33(3):205–20. PMID 11311856

Further Reading and References

Disclaimer

This article is produced for educational and research purposes only. Peptidings does not provide medical advice, diagnosis, or treatment recommendations. Nothing in this article should be interpreted as an endorsement of any compound for human use outside of properly conducted clinical trials.

Thymosin beta-4 (Tβ4) is not approved by the U.S. Food and Drug Administration for any therapeutic indication and is prohibited in competitive sport under WADA regulations. Readers are responsible for understanding and complying with applicable laws.

All citations link to primary sources where available. Where cited studies are limited to animal models or early-phase trials, that limitation is stated explicitly and not minimized.

← Previous

GHK-Cu

Resources & Further Research

Where to Go From Here

The services below have been selected by the Peptidings editorial team as resources worth your time, based on evidence standards, clinical oversight, and relevance to the compound covered above.

Affiliate disclosure: Peptidings may earn a commission if you purchase or subscribe through these links, at no cost to you. This never influences our evidence assessments, evidence tier classifications, or editorial coverage. Full disclosure policy →

Telehealth Options

Happy Head

A telehealth platform founded by board-certified dermatologists specializing in hair loss. Offers custom-compounded topical and oral treatments including finasteride, dutasteride, and minoxidil combinations — prescribed and personalized by physicians, delivered to your door.

View Treatment Options →

All links above are affiliate links. We may earn a commission if you subscribe, at no cost to you.

Scroll to Top